Skip to contents

Scott D. Solomon, MD
Senior Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School
Director, Noninvasive Cardiology

Brigham and Women's Hospital
Department of Medicine
Cardiovascular
75 Francis Street
Boston, MA 02115

Email: ssolomon@rics.bwh.harvard.edu

Edit Profile


Research Narrative:

Scott D. Solomon, MD is The Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. He directs the Cardiac Imaging Core Laboratory and the Clinical Trials Endpoints Center at Brigham and Women’s Hospital. He received his A.B. from Williams College and his M.D. from Harvard Medical School.


Dr. Solomon’s research interests have focused on changes in ventricular structure and function following myocardial injury, modifiers of risk and influences of outcome in patients following myocardial infarction and with chronic heart failure, cardiovascular safety of non-cardiovascular therapies, factors that influence the transition from hypertension to heart failure, and heart failure with preserved ejection fraction. He has pioneered the use of cardiac imaging in cardiovascular drug and device development and use of imaging in clinical trials. He and his research group have played a leading role in many international clinical trials in heart failure, hypertension and myocardial infarction, including the SAVE, HEART, VALIANT, CHARM, PEACE, OVERTURE, MADIT- CRT, ALOFT, ALLAY, TREAT, RED-HF, ALTITUDE, FREEDOM, TOPCAT trials. He led the NIH- sponsored Celecoxib Cross-trials Safety Study which directly informed regulatory agencies about the safety of widely used non-steroidal anti-inflammatory agents. He directs the Cardiac Imaging Center for the NHLBI Atherosclerosis Risk in Communities (ARIC) study and Hispanic Community Health Study – Study of Latinos (HCHS-SOL), the two largest NIH cohort studies. He is PI of the NHLBI sponsored INVESTED trial studying the role of inluenza vaccine in preventing morbidity and mortality in high-risk cardiovascular patients.

Dr. Solomon has recently studied the role for angiotensin receptor neprilysin inhibition in heart failure. He served as member of the executive committee for the PARADIGM-HF trial, led the first successful Phase II trial in heart failure with preserved ejection fraction and is currently leading the ongoing PARAGON-HF outcomes trial in HFpEF.

Dr. Solomon leads a research group consisting of 6 faculty members, 8 research fellows and 30 support staff. He currently receives, or has received, extensive research support from the NIH and multiple industry sponsors. He has directed the Harvard Medical School Cardiovascular Clerkship and the Echocardiography training program at Brigham and Women’s Hospital. He has authored more than 400 peer-reviewed articles, reviews and editorials, two textbooks of cardiac imaging, and the Echocardiograph/Imaging sections for the 10 th edition of Braunwald’s Heart Disease and 19 th edition Harrison’s Principles of Internal Medicine. He is listed by Thomson-Reuters as one of the most highly cited scientists in the past 10 years. He is a Cardiology Section Editor at UpToDate and International Associate Editor at The European Heart Journal.


Education:
Harvard Medical School , 1986, MD
Williams College, 1981, AB

Publications (Pulled from Harvard Catalyst Profiles):

1. Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 Aug 06; 74(5):601-612.

2. Chandra A, Seidelmann SB, Claggett BL, Klein BE, Klein R, Shah AM, Solomon SD. The association of retinal vessel calibres with heart failure and long-term alterations in cardiac structure and function: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2019 Aug 01.

3. Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Shah AM, Lewis EF, Rouleau J, Pitt B, Solomon SD. Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail. 2019 Jul 22.

4. McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019 Jul 15.

5. Minamisawa M, Seidelmann SB, Claggett B, Hegde SM, Shah AM, Desai AS, Lewis EF, Shah SJ, Sweitzer NK, Fang JC, Anand IS, O'Meara E, Rouleau JL, Pitt B, Solomon SD. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2019 Aug; 7(8):664-675.

6. Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 Jul 10.

7. Myhre PL, Vaduganathan M, Solomon SD. Reply: Searching for Optimal Prognostic Marker of Heart Failure Progression in the Era of ARNI. J Am Coll Cardiol. 2019 Jul 09; 74(1):165-166.

8. Solomon SD. Response by Solomon to Letter Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study". Circulation. 2019 Jul 09; 140(2):e92-e93.

9. Shen L, Rørth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, Latini R, Køber L, Anand IS, Carson PE, Granger CB, Komajda M, McKelvie RS, Solomon SD, Staszewsky L, Swedberg K, Huynh T, Zile MR, Jhund PS, McMurray JJV. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 Aug; 21(8):974-984.

10. Selvaraj S, Claggett B, Shah SJ, Anand IS, Rouleau JL, Desai AS, Lewis EF, Vaduganathan M, Wang SY, Pitt B, Sweitzer NK, Pfeffer MA, Solomon SD. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 Jul; 12(7):e006125.